Fig. 1.

Possible roles for Pannexin 1 (PANX1) in COVID-19 pathology. Pannexin intracellular loop 2 peptide (PxIL2P) could potentially be commercialized for specific PANX1 inhibition of inflammatory cues (e.g., IL-1β). Probenecid, an FDA-approved drug used in the treatment of gout, could help dampen the hyperinflammation observed in COVID-19 and could also have an impact on the life cycle of the virus. In addition to affecting the life cycle of the virus, remdesivir could potentially impact inflammation through blocking PANX1.